Vedolizumab
Vedolizumab (pronounced vee-doh-LIZ-uh-mab) is a medication used in the treatment of Ulcerative Colitis and Crohn's Disease, two types of Inflammatory Bowel Disease (IBD).
Etymology
The name "Vedolizumab" is derived from the Latin "vedo", meaning "I see", and "lizumab", a common suffix for monoclonal antibodies.
Pharmacology
Vedolizumab is a monoclonal antibody that works by blocking the movement of white blood cells into the inflamed gut tissue, thereby reducing inflammation and damage. It specifically targets the α4β7 integrin, a protein on the surface of certain white blood cells.
Usage
Vedolizumab is used in the treatment of moderate to severe ulcerative colitis and Crohn's disease in patients who have not responded well to other treatments. It is administered via intravenous infusion.
Side Effects
Common side effects of Vedolizumab include headache, joint pain, nausea, and fever. Serious side effects may include infections, liver problems, and allergic reactions.
Related Terms
External links
- Medical encyclopedia article on Vedolizumab
- Wikipedia's article - Vedolizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski